Kenvue

brand-profile-thumb

Company Headquarters

199 Grandview Road Skillman, NJ 08558 United States

Driving Directions

Brand Description

Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage and propelled forward by science, our iconic brands — including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec® — are recommended by health care professionals and can be trusted by consumers who use our products to improve their daily lives. Our team members share a digital-first mindset, with an approach to innovation grounded in deep human insights and work every day to earn a place for our products in consumers’ hearts and homes. At Kenvue, we believe everyday care can not only make people well; it can make them whole.

Key Personnel

NAME
JOB TITLE
  • Thibaut Mongon
    Chief Executive Officer and Director
  • Ellesha Kirby
    Global Head, Skin Health & Beauty and Design
  • Carlton Lawson
    Group President, Europe, Middle East and Africa
  • Donna Lorenson
    Chief Corporate Affairs Officers
  • Jan Meurer
    Chief Growth Officer
  • Matt Orlando
    General Counsel
  • Rosana Padilla
    President, Latin America
  • Manoj Raghunandanan
    Global Head, Self-care and Consumer Experience Organization
  • Paul Ruh
    Chief Financial Officer
  • Meri Stevens
    Chief Operations Officer
  • Bernardo Tavares
    Chief Scientific Officer
  • Kathy Widmer
    Group President, North America and Latin America
  • Ellie Bing Xie
    Group President, Asia Pacific
  • Natasha Zuyev
    Chief Quality Officer

Yearly results

Sales: 7 Billion

Sales: $7 billion

What’s new? Kenvue! The spinoff of Johnson & Johnson Consumer Brands took place in May, but the move was announced back in September, 2022. At the time of the announcement, J&J explained the name (pronounced ken-view), is inspired by two ideas:

  • “Ken”—meaning knowledge, an English word primarily used in Scotland; and
  • “Vue”—referencing sight.

Johnson’s baby care is part of Kenvue’s offerings.

With rich knowledge of human needs and deep consumer insights, Kenvue will deliver meaningful, personal health solutions, said J&J at the time of the announcement.

Kenvue debuted on the New York Stock Exchange on May 4 under the ticker symbol, KVUE. The initial public offering was priced at $22 a share, and is the largest US IPO in 2023 to date. At $22 a share, Kenvue was valued at $41 billion. A month later, Kenvue was trading at $24.96 a share. Obviously, investors like what they see about a new company with a roster of familiar, well-known brands like Johnson’s, Listerine and Neutrogena.

Kenvue is well positioned for accelerated growth following its separation from parent company Johnson & Johnson, according to JPMorgan. The investment bank said that it views both Kenvue’s dividend and valuation as “attractive,” with the company “uniquely positioned” to capitalize on “mega trends” in consumer markets such as self-care and aging. It noted that 10 of Kenvue’s products have annual sales above $400 million, including Aveeno, Band-Aid, Neutrogena, Stayfree/Carefree, Tylenol and Zyrtec.

JP Morgan told investors that Kenvue will deliver “resilient growth” in a market worth $369 billion. Further, the bank sees “significant opportunities to scale in many adjacencies and markets around the world organically and through tuck-in M&A.”

JP Morgan set a December 2023 price target of $29.

Kenvue’s 2022 sales were $15 billion, but that total includes cough and cold medicines, pain relievers and other self-care products. Happi estimates sales in our industry come in at $7 billion. By segment, face & body care represent 20% of sales, with hair, sun & other, oral care and baby care each accounting for 9% of sales.

For Q1 2023, corporate sales rose 7% to $3.8 billion. Skin health and beauty segment sales rose nearly 10% to over $1.1 billion. Kenvue credited the gain, in part, to strong e-commerce and club channel performance primarily in the US, driven by new product launches, supply chain constraints easing, one-time supply replenishment and sun season pipeline fill.

Related Content